Mark Cohen

Top rated Intellectual Property attorney in New York, New York

Pearl Cohen Zedek Latzer Baratz LLP
Mark Cohen
Pearl Cohen Zedek Latzer Baratz LLP

Practice Areas: Intellectual Property, Technology Transactions; view more

Licensed in New York since: 1994

Education: University of Baltimore School of Law

Selected to Super Lawyers: 2019 - 2023

Pearl Cohen Zedek Latzer Baratz LLP

7 Times Square
Times Square Tower
New York, NY 10036 Visit website


Representing clients ranging from startup ventures to Fortune 500 companies, Mark Cohen is a founder and senior partner at the law firm of Pearl Cohen Zedek Latzer Baratz. Focusing his practice on intellectual property, Mr. Cohen generally handles cases involving matters such as patent licensing and litigation, intellectual property transactions and management, and agreement drafting and negotiations.

After earning a Bachelor of Arts in biochemistry from Rutgers, The State University of New Jersey in 1989, Mr. Cohen went on to attend New York University. From there, he graduated with a Master of Science in biology in 1990. Mr. Cohen received a Juris Doctor from The University of Baltimore School of Law in 1993.

Helping clients to manage and monetize their intellectual property assets, Mr. Cohen assists entrepreneurs, startup companies, private businesses and global companies with due diligence matters, patentability opinions, licensing matters, opposition proceedings and infringement validity. His experience includes aiding clients in the pharmaceutical; energy, semiconductors and electronics; life sciences, medical technology, automotive, and defense and aerospace areas. Mr. Cohen is admitted to the New York State Bar Association, and the U.S. Patent and Trademark Office.

Involvement in the legal community is a priority for Mr. Cohen. Regularly sharing his knowledge and experience with others, he also lectures before various professional organizations and has published articles in the Nature Biotechnology journal and a number of patent trade journals.

Beyond his work in the legal community, Mr. Cohen was a board member for MaSTherCell which was sold to Catalant, Inc., and he previously served as chairman of the board and chairman of the governance and nominating committee for Akari Therapeutics; and Tarus Therapeutics, Inc.

Practice areas

Intellectual Property, Technology Transactions

Focus areas

Patents, Science and Technology Law

  • 80% Intellectual Property
  • 20% Technology Transactions

First Admitted: 1994, New York

Professional Webpage:

Bar/Professional Activity:
  • I am a member of the New York Bar, and United States Patent and Trademark Office.  
Scholarly Lectures/Writings:
  • Lectured, Practicing Law Institute (PLI)
  • Editor-in-Chief of the University of Baltimore Intellectual Property Law Journal
  • Lectured, American Conference Institute
Educational Background:
  • New York University, M.Sc. Biology, 1990 Rutgers University, B.A. Biochemistry, 1989, 1990
  • Invention, Innovation and Value Creation ( publication date Jun 1, 2013 publication description TEDx publication description. In this TEDx presentation, Mark Cohen explores the difference between "invention" and "innovation" from a technical and legal standpoint and reflects upon the importance of both in the advancement of science, business and technology. The idea is a universal message regarding who participates in the process of innovation as compared to the process of an invention. Innovation is an inclusive process in which individuals with varied backgrounds and experiences participate in the development and success of a product , whereas in the process of an invention is by a few highly skilled individuals and is exclusive. The basis of innovation has macro economic implications that can contribute to our better understanding and achievement of value creation., Invention, Innovation, and Value Creation, 2013
  • December 17, 2017 Vayyar Imaging, the 3D imaging sensor company whose technology makes it possible to see through objects, today announced it has closed a $45 million Series C financing round co-led by Walden Riverwood and ITI with additional funding from Claltech and follow-on investment from Battery Ventures, Bessemer Ventures, Israel Cleantech Ventures, and Amiti, bringing total capital raised to date to $79 million USD. Vayyar will use the funds to expand into new industries, grow its global team and diversify its sensing product offerings. Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, represents Vayyar imaging in its intellectual property and patent matters. December 13, 2017 Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc., (OTCQB:ORGSD) (“Orgenesis” or the “Company”), a vertically-integrated biopharmaceutical company with expertise and unique experience in gene and cell therapy and regenerative medicine, today announced that Orgenesis and Pall Corporation have completed their joint development program supported by the Israel-U.S. Binational Industrial Research and Development (“BIRD”) Foundation. Orgenesis is focused on developing an innovative autologous cell-based therapy for the treatment of diabetes. Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represented Orgenesis in its corporate matters in regard to the transaction December 10, 2017 Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments. Ayala Pharmaceuticals, a biopharmaceutical company dedicated to developing targeted cancer therapies, announced today that they have entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for two gamma secretase inhibitors in development for the treatment of cancers with altered Notch genes. Under the terms of the license agreement, Ayala will have exclusive worldwide development and commercialization rights for BMS-906024 and BMS-986115, two gamma secretase inhibitors previously developed by BMS as a Notch inhibitor for oncology indications. In connection with the license, BMS received an upfront payment, became a shareholder of Ayala, and is eligible to receive certain development, regulatory, and sales-based milestones, as well as tiered annual net sales royalties. Ayala is responsible for all future development and commercialization of BMS-906024 and BMS-986115. Israel Biotech Fund identified the opportunity, led the due diligence and syndicated with aMoon and Harel Insurance in 2017 to form Ayala. The new company intends to develop BMS-906024 as a precision medicine for niche orphan patient populations harboring Notch activating mutations. Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, represents Israel Biotech Fund in intellectual property and patent matters, and was patent counsel for Israel Biotech Fund on the intellectual property diligence of BMS-906024 and BMS-986115. October 1, 2017 Mark Cohen, Senior Partner and member of the Executive Committee and Chair of the Life Science Practice Group, represented GTx, Inc. in intellectual property and patent matters, following a $48.5M Private Placement Agreement. September 24, 2017 Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, represents Enlivex Therapeutics in intellectual property and patent matters. Enlivex Therapeutics, a clinical stage immunotherapy company, announced the closing of an $8 million financing round at a company valuation of $50 million. The financing led by Korea Investment Partners will fund Phase III clinical trials. June 21, 2017 Mark Cohen of Pearl Cohen represented Immune Pharmaceuticals Inc. in its transaction to acquire the rights to Ceplene from Meda A.B., now part of Mylan, a global healthcare company. Ceplene, an advanced drug to treat leukemia, has been shown in clinical studies to prevent leukemic relapses in patients in remission. February 27, 2017 Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, represents Israel Biotech Fund in intellectual property and patent matters, and was patent counsel for Israel Biotech Fund on its intellectual property diligence matters for the $30 million investment in Pharm Two B. July 1, 2016  Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, represents OPKO Health, Inc. in intellectual property and patent matters, and was patent counsel for OPKO Health, Inc. on patent diligence matters for the transaction. OPKO Health, Inc. (NASDAQ:OPK) and Transition Therapeutics Inc. (NASDAQ:TTHI, TSX:TTH) announce the signing of a definitive agreement under which OPKO will acquire Transition Therapeutics, a clinical stage biotechnology company. December 21, 2015  Mark Cohen of Pearl Cohen represented Orgenesis inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company, in raising a $10,000,000 financing and in the acquisition of MaSTherCell, an advanced cell therapy and bio-manufacturing company based in Europe. September 24, 2015 Mark Cohen, Senior Partner and Chair of the Life Science Group, is as a result of the merger and financing the Vice Chairman of Akari Therapeutics. Akari Therapeutics (formerly known as Celsus Therapeutics plc) (NASDAQ: AKTX), announced that it has closed a previously announced private placement financing with a select group of investors, led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors. The private placement, which follows the Company’s completion of its acquisition of Volution Immuno Pharmaceuticals SA announced on September 18, 2015, valued the combined entity at $150 million on a fully-diluted basis prior to the completion of the private placement. December 15, 2014  Mark Cohen of Pearl Cohen was lead intellectual property counsel to OPKO Health, Inc. in its negotiations with Pfizer Inc. that resulted in a global agreement for the development and commercialization of OPKO’s long-acting hGH-CTP product for the treatment of pediatric and adult growth hormone deficiency (GHD). Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide. OPKO Health Signs $570 million Deal with Pfizer for Global Agreement for OPKO’s Human Growth Hormone., 2014
Representative Clients:
  • University of Pennsylvania Memorial Sloan Kettering Cancer Center  Regents of the Univeristy of California Los Angeles (UCLA) The Weizmann Institute Eli Lilly and Company  OPKO, Inc.  Veru, Inc  Orgenesis Humanigen  Arkin Fund Israel Biotech Fund, 2017, 2023
Industry Groups:
  • Biotechnology/pharmaceuticals/chemistry/medical Device

Office location for Mark Cohen

7 Times Square
Times Square Tower
New York, NY 10036

Phone: 646-878-0804


5 Years Super Lawyers
  • Super Lawyers: 2019 - 2023

Attorney resources for Mark Cohen

Page Generated: 0.14856505393982 sec